# Insamo

**Canonical:** https://apis.io/providers/insamo/  
**Website:** https://insamo.com/  
**APIs profiled:** 0

Insamo is a biotechnology company building membrane-permeable, orally available cyclic peptides that combine the binding affinity of antibodies with the pharmacology of small molecules for drug discovery. Its platform automates the design, synthesis, and testing of peptides at large scale and applies machine learning across vast chemical spaces to identify therapeutic candidates. Founded in February 2024 with $12M from Playground Global, venBio, and MRL Ventures Fund, the company operates from Berkeley, California and Chippendale, New South Wales, Australia. Insamo currently publishes no public developer or API surface; this profile tracks the company in the API Evangelist network.

## Kin Score — 5.0 / 100 (minimal)

Scored 2026-08-20 under rubric 0.12.0. Trend: flat (+0.0 from 5.0).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 0.0 |
| Access Clarity | 0.0 |

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Security (1)

- **Insamo Domain Security** — TLSv1.3 · HSTS

## Tags

Company, Engineered Biology, Biotechnology, Drug Discovery, Peptides, Machine-Learning, Therapeutics

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/insamo/). Scores are computed from the provider's own public artifacts under a published rubric.